JP2020535799A - 新規の安定した抗体の可変領域フレームワークの組み合わせ - Google Patents

新規の安定した抗体の可変領域フレームワークの組み合わせ Download PDF

Info

Publication number
JP2020535799A
JP2020535799A JP2020515647A JP2020515647A JP2020535799A JP 2020535799 A JP2020535799 A JP 2020535799A JP 2020515647 A JP2020515647 A JP 2020515647A JP 2020515647 A JP2020515647 A JP 2020515647A JP 2020535799 A JP2020535799 A JP 2020535799A
Authority
JP
Japan
Prior art keywords
seq
set forth
sequence
antibody
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535799A5 (https=
Inventor
ディーム ダニア
ディーム ダニア
ヘス クリスティアン
ヘス クリスティアン
マイアー ゼバスティアン
マイアー ゼバスティアン
ユーレヒ ダービト
ユーレヒ ダービト
Original Assignee
ヌマブ セラピューティクス アクチェンゲゼルシャフト
ヌマブ セラピューティクス アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌマブ セラピューティクス アクチェンゲゼルシャフト, ヌマブ セラピューティクス アクチェンゲゼルシャフト filed Critical ヌマブ セラピューティクス アクチェンゲゼルシャフト
Publication of JP2020535799A publication Critical patent/JP2020535799A/ja
Publication of JP2020535799A5 publication Critical patent/JP2020535799A5/ja
Priority to JP2023090016A priority Critical patent/JP2023115024A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020515647A 2017-09-20 2018-09-19 新規の安定した抗体の可変領域フレームワークの組み合わせ Pending JP2020535799A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090016A JP2023115024A (ja) 2017-09-20 2023-05-31 新規の安定した抗体の可変領域フレームワークの組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192206.5 2017-09-20
EP17192206.5A EP3459968A1 (en) 2017-09-20 2017-09-20 Novel stable antibody variable domain framework combinations
PCT/EP2018/075377 WO2019057787A1 (en) 2017-09-20 2018-09-19 NEW STABLE COMBINATIONS OF VARIABLE DOMAINS OF ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090016A Division JP2023115024A (ja) 2017-09-20 2023-05-31 新規の安定した抗体の可変領域フレームワークの組み合わせ

Publications (2)

Publication Number Publication Date
JP2020535799A true JP2020535799A (ja) 2020-12-10
JP2020535799A5 JP2020535799A5 (https=) 2021-11-04

Family

ID=59982265

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515647A Pending JP2020535799A (ja) 2017-09-20 2018-09-19 新規の安定した抗体の可変領域フレームワークの組み合わせ
JP2023090016A Pending JP2023115024A (ja) 2017-09-20 2023-05-31 新規の安定した抗体の可変領域フレームワークの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090016A Pending JP2023115024A (ja) 2017-09-20 2023-05-31 新規の安定した抗体の可変領域フレームワークの組み合わせ

Country Status (8)

Country Link
US (2) US11421035B2 (https=)
EP (2) EP3459968A1 (https=)
JP (2) JP2020535799A (https=)
CN (1) CN111133000A (https=)
AU (1) AU2018335823B2 (https=)
CA (1) CA3073882A1 (https=)
MA (1) MA50159A (https=)
WO (1) WO2019057787A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243311B (en) * 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
KR20230123981A (ko) 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-4r에 결합하는 항체 가변 도메인
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
EP4019546A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-31
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
WO2022171771A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
CR20240265A (es) 2021-12-22 2024-10-16 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
AU2023265474A1 (en) 2022-05-06 2024-10-31 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
AU2024275787A1 (en) 2023-05-19 2025-11-27 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2025133389A1 (en) 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523012A (ja) * 2005-12-29 2009-06-18 セントカー・インコーポレーテツド ヒト抗ｉｌ−２３抗体、組成物、方法および用途
JP2016523537A (ja) * 2013-06-26 2016-08-12 ヌマブ アクチェンゲゼルシャフト 新規抗体フレームワーク
JP2016539632A (ja) * 2013-10-25 2016-12-22 ヌマブ アクチェンゲゼルシャフト 二重特異性構築物と種々の疾患の治療におけるその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523012A (ja) * 2005-12-29 2009-06-18 セントカー・インコーポレーテツド ヒト抗ｉｌ−２３抗体、組成物、方法および用途
JP2016523537A (ja) * 2013-06-26 2016-08-12 ヌマブ アクチェンゲゼルシャフト 新規抗体フレームワーク
JP2016539632A (ja) * 2013-10-25 2016-12-22 ヌマブ アクチェンゲゼルシャフト 二重特異性構築物と種々の疾患の治療におけるその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MOLECULAR BIOLOGY, vol. 296, JPN6022014280, 2000, pages 57 - 86, ISSN: 0004748769 *

Also Published As

Publication number Publication date
EP3684802A1 (en) 2020-07-29
WO2019057787A1 (en) 2019-03-28
US11421035B2 (en) 2022-08-23
AU2018335823A1 (en) 2020-02-27
US20200255533A1 (en) 2020-08-13
CN111133000A (zh) 2020-05-08
AU2018335823B2 (en) 2025-09-04
MA50159A (fr) 2020-07-29
EP3459968A1 (en) 2019-03-27
US20230242651A1 (en) 2023-08-03
JP2023115024A (ja) 2023-08-18
CA3073882A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US20230242651A1 (en) Stable antibody variable domain framework combinations
US20220267440A1 (en) Anti-cd47 antibodies
US20220403028A1 (en) Novel anti-cd3 antibodies
KR102942600B1 (ko) 항-pd-1 항체, 이의 항원-결합 단편 및 이의 약학적 용도
EP3634997B1 (en) Anti-hsa antibodies
CN116940596A (zh) 结合il-31的抗体可变结构域
WO2018224439A1 (en) Novel anti-hsa antibodies
JP2025529812A (ja) 甲状腺刺激ホルモン受容体に結合する抗体及びその使用
WO2018224441A1 (en) Novel anti-cd3 antibodies
US20240084039A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
HK40027107B (en) Anti‑cd3 epsilon antibodies
HK40027107A (en) Anti‑cd3 epsilon antibodies
HK40023336A (en) Anti-hsa antibodies
HK40023336B (en) Anti-hsa antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804